In vivo, long-term recombinant IL-33 treatment delayed the disease onset on female mice in a transgenic mouse model of ALS expressing SOD1-G93A while male mice remained unresponsive. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.